NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation into potential security claims on behalf of shareholders of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) arising from allegations that Accelerate Diagnostics may be providing materially misleading business information to the investing public Has .

SO WHAT: If you have purchased Accelerate Diagnostics securities, you may be entitled to compensation without payment of expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=9377 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action.

WHAT IS THIS ABOUT: On October 21, 2022, after the close of trading, Accelerate Diagnostics filed an update report with the SEC on Form 8-K disclosing that, pursuant to discussions with the U.S. Food and Drug Administration (“FDA”), Accelerate Diagnostics among other things: “(i) Discontinu[e] the US marketing and distribution of [its Accelerate Arc system and related BC Kit (collectively, the “Accelerate Arc Products”)] for processing positive blood cultures and subsequent identification by mass spectrometry for diagnostic purposes; (ii) remove[e] and/or correct[] any US promotional information within the Company’s control (e.g., website, labeling, social media, sales representative information, or other promotional material) relating to the diagnostic use of the Accelerate Arc products as Class I devices or as devices classified as positive blood culture processing equipment is provided for subsequent identification of microorganisms by mass spectrometry; and (iii) revise[e]/remove[e] the registration and listing by the Company of Accelerate Arc products as Class I devices.”

…